GenSight Biologics Provides Update on Operations in the Context of COVID-19

GenSight Biologics announces presentation of bilateral visual recovery from GS010 (LUMEVOQ™) Phase III trials at the 46th annual meeting of NANOS

2020 Cell & Gene Meeting on the Mediterranean, Barcelona, Spain – cancelled

Bio Europe Spring, Paris, France

46th NANOS Annual Meeting, Amelia Island, Florida, US

GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history

The Quinze-Vingts Hospital and GenSight Biologics announce a first Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France

38th Annual J.P. Morgan Healthcare Conference, San Francisco (CA), USA

3rd Annual Gene Therapy for Rare Disorders Europe, London (UK)

GenSight Biologics reports evidence of GS010 DNA transfer to contralateral eye of primates unilaterally injected with GS010 Gene Therapy